DRUG DISCOVERY
RevolKa is developing its own drug discovery pipeline targeting inherited metabolic diseases using proprietary designs powered by aiProtein®.
| As of January 31, 2025 | |||||||
| Project | Indication | Partner | Discovery／Preclinical | Clinical | |||
| Lead Discovery |
Preclinical | Ph1 | Ph2 | Ph3 | |||
| RKD001 | Rare Disease |
 |
 |
||||
| RKD002 | Rare Disease |
|
|
||||
| RKD003 | Rare Disease |
|
|
||||
| RKD004 | Rare Disease |
Undisclosed | |
||||